Comparative Pharmacology
Head-to-head clinical analysis: CLOZARIL versus REXULTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOZARIL versus REXULTI.
CLOZARIL vs REXULTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clozapine is an atypical antipsychotic that binds to multiple receptors including dopamine D1-D5 (with greater affinity for D4), serotonin 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, 5-HT7, histamine H1, muscarinic M1-M5, and adrenergic α1- and α2-receptors. Its therapeutic efficacy is primarily attributed to antagonism of D2 and 5-HT2A receptors. It also has weak D2 antagonism and rapid dissociation from D2 receptors, which may contribute to lower extrapyramidal side effects.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Initial 12.5 mg orally once or twice daily, titrate by 25-50 mg/day over 2 weeks to target 300-450 mg/day in divided doses; max 900 mg/day.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 8–12 hours at steady state; range 6–26 hours, increasing with dose due to saturable metabolism.
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Approximately 50% excreted renally as metabolites, with less than 1% unchanged; 30% eliminated in feces via biliary excretion.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic